What is the chance of a normal pregnancy in a woman whose fetus has been exposed to isotretinoin?

Archives of Dermatology

Volumn 143, Issue 9, 2007, Pages 1187-1188

  Sladden, Michael J ^a   Harman, Karen E ^b  

^a UNIVERSITY OF TASMANIA   (Australia)

^b LEICESTER ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ETHINYLESTRADIOL PLUS LEVONORGESTREL; ISOTRETINOIN;

AORTA ARCH ANOMALY; BRAIN CORTEX LESION; CARDIOVASCULAR MALFORMATION; CENTRAL NERVOUS SYSTEM MALFORMATION; CEREBELLUM DISEASE; CLEFT PALATE; CONGENITAL MALFORMATION; CRANIOFACIAL MALFORMATION; DRUG EXPOSURE; EAR MALFORMATION; ECTOPIC TISSUE; EMBRYOPATHY; FACE DYSMORPHIA; FACIAL NERVE PARALYSIS; FALLOT TETRALOGY; FETUS MALFORMATION; GREAT VESSELS TRANSPOSITION; HEART ATRIUM SEPTUM DEFECT; HUMAN; HYDROCEPHALUS; HYPERTELORISM; LIMB REDUCTION DEFECT; MICROCEPHALY; NOTE; OUTCOME ASSESSMENT; PATIENT MONITORING; PREGNANCY; PRENATAL EXPOSURE; PRIORITY JOURNAL; SPINA BIFIDA; SPONTANEOUS ABORTION; TERATOGENICITY; THYROID DYSGENESIS;

ABNORMALITIES, DRUG-INDUCED; FEMALE; FETUS; HUMANS; INFANT, NEWBORN; ISOTRETINOIN; PREGNANCY;

EID: 34548823808     PISSN: 0003987X     EISSN: 0003987X     Source Type: Journal    
DOI: 10.1001/archderm.143.9.1187     Document Type: Note

References (13)

1. Lindstrom J. Isotretinoin: background and regulatory history. FDA Joint Dermatologic and Ophthalmic Drugs & Drug Safety and Risk Management Advisory Committee Meeting; February 26-27, 2004; Gaithersburg, MD. http://www.fda.gov/ ohrms/dockets/ac/04/slides/4017s1.htm. Accessed March 12, 2007.
2. Abroms L, Maibach E, Lyon-Daniel K, Feldman SR. What is the best approach to reducing birth defects associated with isotretinoin? PLoS Med. 2006;3(11):e483.
3. Dai WS, LaBraico JM, Stern RS. Epidemiology of isotretinoin exposure during pregnancy. J Am Acad Dermatol. 1992;26(4):599-606.
4. Lammer EJ, Chen DT, Hoar RM, et al. Retinoic acid embryopathy. N Engl J Med. 1985;313(14):837-841.
5. Mitchell AA, Van Bennekom CM, Louik C. A pregnancy-prevention program in women of childbearing age receiving Isotretinoin. N Engl J Med. 1995;333(2):101-106.
6. Bérard A, Azoulay L, Koren G, Blais L, Perreault S, Oraichi D. Isotretinoin, pregnancies, abortions and birth defects: a population-based perspective. Br J Clin Pharmacol. 2007;63(2):196-205.
7. Lynberg MC, Khoury MJ, Lammer EJ, Waller KO, Cordero JF, Erickson JD. Sensitivity, specificity, and positive predictive value of multiple malformations in isotretinoin embryopathy surveillance. Teratology. 1990;42(5):513-519.
8. Stern RS, Rosa F, Baum C. Isotretinoin and pregnancy. J Am Acad Dermatol. 1984;10(5, pt 1):851-854.
9. Adams J, Lammer EJ. Neurobehavioral teratology of isotretinoin. Reprod Toxicol. 1993;7(2):175-177.
10. National Teratology Information Service. Exposure to Isotretinoin During Pregnancy. Newcastle upon Tyne, England: National Teratology Information Service, Regional Drug and Therapeutics Centre; 2001.
11. Food and Drug Administration. iPLEDGE update. 2006. http://www.fda.gov/ cder/drug/infopage/accutane/iPLEDGEupdate200603.htm. Accessed May 28, 2007.
12. Goldsmith LA, Bolognia JL, Callen JP, et al. American Academy of Dermatology Consensus Conference on the safe and optimal use of isotretinoin: summary and recommendations [published correction for a dosage error appears in J Am Acad Dermatol. 2004;51(3):348]. J Am Acad Dermatol. 2004;50(6):900-906.
13. Rothman KF, Pochi PE. Use of oral and topical agents for acne in pregnancy. J Am Acad Dermatol. 1988;19(3):431-442.